Back to search

Article

Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the virion membrane

2023-12-22

Abstract excerpt

<title>Abstract</title> <p>Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP<sub>1,2</sub>) are the standard of care for Ebola virus disease (EVD). Anti-GP<sub>1,2</sub> mAbs targeting the stalk and membrane proximal external region (MPER) potently neutralize EBOV <italic>in vitro</italic>. However, their neutralization mechanism is poorly understood because they target a GP<sub>1,2</sub> e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a3a7ac13-0d35-50c1-9cfd-7f14a58299d4
DOI
10.21203/rs.3.rs-3722563/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the virion membraneDOI 10.21203/rs.3.rs-3722563/v1
Select a neighboring publication to make it the new centre.